Figure 2 | Scientific Reports

Figure 2

From: A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis

Figure 2

SP-ELISA of 18 sera of JIA patients treated with Adalimumab and 8 sera of untreated patients using CDR region Heavy Chain (HC) and Light Chain (LC) peptides as antigens (Table 1). Anti-Adalimumab antibodies were measured against: (A) HC 1–3 peptide antigens; (B) HC3.1–3.3 peptide antigens; (C) LC 1–3 peptide antigens. Significant differences in terms of absorbance between a group of treated patients and the negative controls is observed only for peptides HC3 and LC3 (p value HC3 = 0.0398, p value LC3 < 0.008).

Back to article page